

BSW Formulary Update – Following APC Nov 2020 meeting

New additions to the BSWformulary

- [Omeprazole 4mg/ml suspension \(Rosemont\)](#) has been included ONLY for use following specialist recommendation for paediatric patients under 1 year of age or under 10kg whereby dispersible tabs/esomeprazole sachets are not appropriate (i.e. prescribed dose under 5mg or feeding tube in situ) AMBER TLS. **Omeprazole suspension is NOT included on the formulary for use outside this cohort (see here).**
- [Remdesivir solution for infusion](#). For use in line with NHSE commissioning intentions. RED TLS
- [Ciclosporin 0.1% eyedrops \(Verkazia\)](#) for severe vernal keratoconjunctivitis in paediatric patients. RED TLS. *Please note Verkazia was already in use at SFT and so this is a new addition for RUH and GWH.* Ciclosporin 0.1% eyedrops ([Ikervis](#)) remain on the formulary for adult patients as an AMBER TLS drug across BSW.
- [Cyanocobalamin 1mg tablets](#) (Orabalin®) – Green TLS use as per BSW guidance on B12 supplements during Covid pandemic [here](#)
- [Pancrex V oral powder](#) (Admin via enteral feeding tubes only) – AMBER TLS
- Liquid formulations of [propranolol and atomoxetine](#) added to existing entries for use in paediatric indications – AMBER TLS
- [Hyaluronidase 1,500unit powder for solution for injection ampoules](#) as adjunct to local anaesthesia in ophthalmology – RED TLS
- [Medi-test protein 2 proteinuria detection strips](#) – GREEN TLS (for the rare occasions where monitoring for nephritis is required)
- [Hydroxychloroquine 300mg tablets](#) (Blackrock) – BLACK TLS (non-formulary).
- [Sotagliflozin 200mg tablets](#). Not available yet in the UK but included for use with insulin for treating type 1 diabetes as per NICE TA622. BSW APC will determine TLS once available (expected early 2021)

Removed from BSWformulary

- [Antazoline 0.5% with Xylometazoline 0.05% eyedrops](#). Self-purchase only.
- [Nedocromil eyedrops](#) – discontinued by manufacturer..

Changes in Traffic Light Status

- [Domperidone](#) aligned for BSW with a GREEN TLS for its licensed indication which is SHORT –TERM relief of symptoms of nausea and vomiting in adults and adolescents over 12 years and weighing more than 35 kg and a GREEN TLS for [gastric pain in palliative care](#). All off-label uses or long term use in

N&V are AMBER TLS. See updated BSW Domperidone prescribing guidance (link below) which incorporates 2019 MHRA safety update.

TLS Aligned for BSW

- **Fentanyl (Patches), Oxycodone (Tablets) and Buprenorphine high strength patches (35, 52.5 and 70microgram patches (those that require changing every 4 days)) are aligned as AMBER TLS when used for chronic pain indications.** See [Here](#). This supports the national steer away from opioid use for chronic non-cancer pain and is in line with [MHRA advice](#) and recommendations to move away from opioids for chronic pain. Also, [NICE guidance \(draft\) on chronic pain](#) notes a lack of evidence for effectiveness of opioids along with evidence of long-term harm when used for chronic primary pain.
- Buprenorphine low strength patches (5, 10, 15 and 20 micrograms (those that require changing every 7 days)) and morphine preparations remain GREEN TLS.
- Transdermal fentanyl remains appropriate for GP initiation for those that cannot swallow oral medicines.
- Fentanyl and oxycodone remain GREEN TLS drugs when used for [palliative care](#) indications to allow timely access for these drugs
- A BSWCCG primary care workstream on deprescribing and reducing the prescribing of dependence forming medicines is underway. Resources and education to support prescribing will be communicated when available. Please also see <https://www.fpm.ac.uk/opioids-aware>

New and Updated Prescribing Guidelines

- **Updated** - [Oral Nutrition Supplements Guidance](#) (sip feeds): outlines the first line and specialist supplements suitable for prescribing by GP's, Nurses and Dietitians with costs and appropriate quantities. Formulary entries have been updated [here](#)
- **Updated** – [BSW Domperidone prescribing guidance](#): incorporates aligned TLS and MHRA safety information.
- **Removed** – 3Ts/AWP SCA foracamprosate has been removed. Alcohol services are no longer commissioned from AWP for Swindon.
- **Removed** – BCAP SCA for Rotigotine for PD has been removed. It was agreed that clinically this SCA is no longer required.

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswccg.formulary@nhs.net

What the BSW CCG formulary team are currently working on

- Producing a policy/pathway and prescribing criteria for use of melatonin
- Updating the Vitamin D guidance
- Updating the Vitamin B12 guidance
- Updating the constipation guidance
- Updating the pain management documents
- Reviewing formulary position of Cox-2 inhibitors
- Position statements on various devices
- Aligning Shared Care Agreements across BSW starting with document on DMARD monitoring
- Working with AWP on an oral antipsychotic SCA